Skip to main content
Home > Week in Review > Offerings

Chronological Index of : Financial News

 Current Issue
  • NuSirt Biopharma completes venture financing

    NuSirt Biopharma Inc., Nashville, Tenn. Business: Endocrine/Metabolic, Hepatic, Inflammation Date completed: 2015-05-13 Type: Venture financing Raised: $6 million Investors: Hatteras Venture Partners; Mountain Group …

    Published on 5/18/2015
  • OncoCyte completes venture financing

    OncoCyte Corp., Alameda, Calif. Business: Cancer, Gene/Cell therapy Date completed: 2015-05-14 Type: Venture financing Raised: $3.3 million Investor: Existing investors Note: The company also converted $3.3 million of …

    Published on 5/18/2015
  • Precision BioSciences completes venture financing

    Precision BioSciences Inc., Durham, N.C. Business: Genomics Date completed: 2015-05-11 Type: Venture financing Raised: $25.6 million Investors: VenBio LLC; Fidelity Biosciences; Amgen Ventures; Baxter Ventures; Osage …

    Published on 5/18/2015
  • Prima BioMed completes private placement

    Prima BioMed Ltd. (ASX:PRR; NASDAQ:PBMD), Sydney, Australia Business: Cancer, Infectious Date completed: 2015-05-14 Type: Private placement Raised: A$1.2 million ($985,722) Shares: 72.2 million Price: A$0.02 Shares …

    Published on 5/18/2015
  • Sensorion completes IPO

    Sensorion S.A. (Euronext:ALSEN), Clapiers, France Business: Other Date completed: 2015-04-16 Type: IPO Raised: EUR8.2 million ($8.8 million) Shares: 1.8 million Price: EUR4.54 Shares after offering: 5.1 million …

    Published on 5/18/2015
  • Affimed financial update

    Affimed N.V. (NASDAQ:AFMD), Heidelberg, Germany Business: Cancer, Inflammation, Antibodies Date announced: 2015-05-12 Note: Affimed raised $5.4 million through the sale of 750,000 shares at $7.15 to cover the …

    Published on 5/18/2015
  • aTyr financial update

    aTyr Pharma Inc. (NASDAQ:LIFE), San Diego, Calif. Business: Hematology, Inflammation, Cancer Date announced: 2015-05-12 Note: aTyr raised $11.3 million through the sale of 804,000 shares at $14 to cover the …

    Published on 5/18/2015
  • Bavarian Nordic financial update

    Bavarian Nordic A/S (CSE:BAVA), Kvistgaard, Denmark Business: Infectious, Cancer Date announced: 2015-05-12 Note: Bavarian Nordic secured a three- to five-year, EUR50 million ($55.8 million) unsecured loan facility from…

    Published on 5/18/2015
  • Collegium financial update

    Collegium Pharmaceutical Inc. (NASDAQ:COLL), Canton, Mass. Business: Drug delivery, Neurology, Inflammation Date announced: 2015-05-12 Note: Collegium raised $10.4 million through the sale of 870,000 shares at $12 to …

    Published on 5/18/2015
  • EryDel financial update

    EryDel S.p.A., Urbino, Italy Business: Drug delivery, Neurology Date announced: 2015-05-11 Note: EryDel raised EUR14.5 million ($16.2 million) in a second close of a series B round, bringing the total raised in the …

    Published on 5/18/2015
  • MPM Capital financial update

    MPM Capital, Cambridge, Mass. Business: Finance Date announced: 2015-05-14 Note: MPM Capital closed its BioVentures 2014 fund at $400 million. According to an SEC filing from last spring, MPM was looking to raise about…

    Published on 5/18/2015
  • University of Oxford financial update

    University of Oxford, Oxford, U.K. Business: Finance Date announced: 2015-05-14 Note: The universitys Isis Innovation Ltd. tech transfer arm raised L210 million ($324 million) for its newly formed Oxford Sciences …

    Published on 5/18/2015
  • Gelesis postpones IPO

    Gelesis Inc., Boston, Mass. Business: Endocrine/Metabolic Date announced: 2015-05-13 Type: IPO Underwriters: Piper Jaffray; Stifel, Nicolaus; Guggenheim Securities Note: Gelesis postponed its IPO on NASDAQ. In late …

    Published on 5/18/2015
  • Axovant Sciences proposes IPO

    Axovant Sciences Ltd., Hamilton, Bermuda Business: Neurology Date announced: 2015-05-11 Type: IPO To be raised: Up to $172.5 million Shares: TBD Price: TBD Underwriters: Jefferies; Evercore; RBC Capital Markets; JMP …

    Published on 5/18/2015
  • Biotie proposes follow-on

    Biotie Therapies Corp. (HSE:BTH1V), Turku, Finland Business: Neurology, Autoimmune, Inflammation Date announced: 2015-05-14 Type: Follow-on To be raised: Up to $60 million Shares: TBD Price prior: EUR0.14 Underwriters: …

    Published on 5/18/2015
  • Catabasis Pharmaceuticals proposes IPO

    Catabasis Pharmaceuticals Inc., Cambridge, Mass. Business: Endocrine/Metabolic, Inflammation, Autoimmune Date announced: 2015-05-13 Type: IPO To be raised: Up to $75 million Shares: TBD Price: TBD Underwriters: …

    Published on 5/18/2015
  • Circassia proposes placing and open offer

    Circassia Pharmaceuticals plc (LSE:CIR), Oxford, U.K. Business: Inflammation Date announced: 2015-05-15 Type: Placing and open offer To be raised: L275 million ($424.2 million) Shares: 95.5 million Price: 288.05p …

    Published on 5/18/2015
  • Glaukos proposes IPO

    Glaukos Corp., Laguna Hills, Calif. Business: Ophthalmic Date announced: 2015-05-12 Type: IPO To be raised: Up to $86.3 million Shares: TBD Price: TBD Underwriters: JPMorgan; BofA Merrill Lynch; Goldman Sachs; William …

    Published on 5/18/2015
  • Healios proposes IPO

    Healios K.K., Tokyo, Japan Business: Ophthalmic, Gene/Cell therapy Date announced: 2015-05-12 Type: IPO To be raised: TBD Shares: 10.1 million Price: TBD Underwriters: Nomura; Mizuho; Daiwa Co. Ltd.; SMBC Nikko Capital …

    Published on 5/18/2015
  • Nivalis Therapeutics proposes IPO

    Nivalis Therapeutics Inc., Boulder, Colo. Business: Pulmonary, Inflammation, Autoimmune Date announced: 2015-05-13 Type: IPO To be raised: Up to $60 million Shares: TBD Price: TBD Underwriters: Cowen; Stifel, Nicolaus; …

    Published on 5/18/2015
  • Prima BioMed proposes private placement of convertible notes

    Prima BioMed Ltd. (ASX:PRR; NASDAQ:PBMD), Sydney, Australia Business: Cancer, Infectious Date announced: 2015-05-14 Type: Private placement of convertible notes To be raised: A$13.8 million ($10.9 million) Shares: TBD …

    Published on 5/18/2015
  • Auris Medical amends follow-on

    Auris Medical Holding AG (NASDAQ:EARS), Zug, Switzerland Business: Other Date announced: 2015-05-04 Type: Follow-on To be raised: Up to $33.3 million Shares: 6 million Price prior: $5.40 Underwriters: Leerink Partners; …

    Published on 5/11/2015
  • BiondVax amends follow-on

    BiondVax Pharmaceuticals Ltd. (Tel Aviv:BNDX), Ness Ziona, Israel Business: Infectious Date announced: 2015-05-07 Type: Follow-on To be raised: Up to $12.3 million Shares: 1.5 million Price prior: NIS0.66 Underwriter: …

    Published on 5/11/2015
  • Biotie amends private placement of convertible notes and warrants

    Biotie Therapies Corp. (HSE:BTH1V), Turku, Finland Business: Neurology, Autoimmune, Inflammation Date announced: 2015-05-07 Type: Private placement of convertible notes and warrants To be raised: Up to EUR33.1 million…

    Published on 5/11/2015
  • DelMar Pharma amends follow-on

    DelMar Pharmaceuticals Inc. (OTCQX:DMPI), Vancouver, B.C. Business: Cancer Date announced: 2015-05-07 Type: Follow-on To be raised: $7 million Shares: TBD Price prior: $0.71 Underwriters: Maxim Group; Roth Capital …

    Published on 5/11/2015

< Previous   1  2  3  4  5  6  7  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993